Yersinia pestis, the causative agent of plague, is arguably the most devastating pathogen in human history. Paleogenomic studies indicate its presence as early as the Neolithic era. It evolved from Yersinia pseudotuberculosis, with divergence estimates ranging from 1500 to 20,000 years ago, most often placed around 5000 years ago. Its natural reservoirs are wild mammals, particularly rodents, with fleas serving as vectors, while humans are incidental hosts. Over time, Y. pestis has acquired multiple virulence factors that disrupt immune responses and can lead to rapid, often fatal disease. Because the bacterium is maintained in wildlife cycles and can spill over to domestic animals, eradication is difficult, if not impossible. Nevertheless, mitigation is achievable using a One Health approach integrating human health, animal health, and the health of the environment. Neither vaccines nor monoclonal antibodies are currently licensed in most Western countries, thus, antibiotics remain the mainstay of therapy. Timely administration, ideally within 24 h of symptom onset, is critical, particularly in pneumonic forms. Phage therapy is under investigation as a potential treatment. Though often neglected in high-income settings, plague remains endemic in several regions, with the highest burden reported in Madagascar and the Democratic Republic of the Congo.

The escalating global crisis of antimicrobial-resistant (AMR) bacterial infections, along with the continuous threat of viral outbreaks, poses a serious risk to public health worldwide and underscores the urgent need for innovative therapeutic strategies. In this study, mesoporous silica nanoparticles (MSNs) were successfully synthesized and subsequently functionalized with copper to impart broad-spectrum antimicrobial activity. The oxidation state of copper on the MSN surface was modulated through thermal treatments, allowing the evaluation of its influence on antimicrobial efficacy. The modified MSNs were tested against key bacterial pathogens, including Escherichia coli and Staphylococcus aureus, achieving complete bactericidal activity after 2 h of exposure to E. coli. Moreover, as well as influenza A (H1N1) pdm09, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and MS2 bacteriophage (MS2) were evaluated, reaching an efficiency higher than 80%, 90%, and 97%, respectively. The results indicated that copper-modified MSNs exhibit potent antibacterial and antiviral activity, highlighting their potential as an antibiotic-free alternative for preventing microbial infections while mitigating the development of AMR bacteria.

Dengue virus infection remains a significant public health challenge in endemic regions, with growing evidence of autochthonous transmission in Europe. Assessing serological exposure in high-risk populations such as military personnel deployed to endemic areas is essential to quantify exposure risk and support operational decision-making, particularly regarding pre-deployment counselling and risks associated with secondary infection. We conducted a cross-sectional study involving 1355 members of the Italian Armed Forces, measuring anti-dengue IgG antibodies by ELISA and collecting data on deployment history and exposure risk. Overall, IgG seropositivity was 8.12%, with significantly higher prevalence among individuals reporting travel or deployment to endemic regions (24.71%) compared with non-exposed personnel (4.27%). Seropositivity increased with age and correlated with a CDC-derived cumulative dengue risk score (Spearman’s ρ = 0.299, p < 0.0001). A multivariable logistic regression model including age and exposure risk achieved an AUC of 0.75, while machine-learning models provided complementary predictive assessment, with random forest reaching an AUC of 0.79. These findings indicate substantial anti-dengue IgG seropositivity compatible with previous dengue exposure among Italian military personnel, particularly those deployed to endemic settings. The study highlights the need for targeted surveillance and risk-based preventive strategies, and supports the use of exposure-based models to improve epidemiological assessment and inform vaccination strategies in mobile populations.